Ivan R. González: Interesting results from the phase III MECCA trial
Ivan R. González, Medical Oncologist at the Comprehensive Cancer Center, Hospital Ángeles Puebla, shared a post on X:
“Interesting results from the phase III MECCA trial for the initial treatment of HR+ HER2- metastatic breast cancer:
Results:
– PFS: 20.9 months (metronomic capecitabine + AI) vs. 11.9 months (AI).
– HR: 0.58 (95% CI, 0.43-0.76).
– OS: Not reached vs. 45.1 months.
– HR: 0.58 (95% CI, 0.37-0.93).
Adverse events:
– Grade 3: 15.1% (palmar-plantar erythrodysesthesia, peripheral neuropathy).
Metronomic capecitabine + AI significantly improves PFS and OS with a tolerable safety profile.”
Ashish Singh, Professor of Medical Oncology at Christian Medical College Vellore India, shared this post, adding:
“Capecitabine has been a consistent performer across all stages of breast cancer..
also commonly ignored as a control arm option in many of the recent MBC clinical trials.”
Authors: Ruo-Xi Hong et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023